Loading...
XNYS
PFE
Market cap146bUSD
Dec 04, Last price  
25.70USD
1D
0.51%
1Q
3.30%
Jan 2017
-16.53%
Name

Pfizer Inc

Chart & Performance

D1W1MN
XNYS:PFE chart
P/E
18.22
P/S
2.30
EPS
1.41
Div Yield, %
6.54%
Shrs. gr., 5y
0.09%
Rev. gr., 5y
4.22%
Revenues
63.63b
+8.77%
51,298,000,00048,371,000,00048,418,000,00048,296,000,00050,009,000,00067,809,000,00067,425,000,00058,986,000,00051,584,000,00049,605,000,00048,851,000,00052,824,000,00052,546,000,00053,647,000,00051,750,000,00041,908,000,00081,288,000,000100,330,000,00058,496,000,00063,627,000,000
Net income
8.02b
+278.48%
8,085,000,00019,337,000,0008,144,000,0008,104,000,0008,635,000,0008,257,000,00010,009,000,00014,570,000,00022,003,000,0009,135,000,0006,960,000,0007,215,000,00021,308,000,00011,153,000,00016,273,000,0007,020,000,00021,979,000,00031,372,000,0002,119,000,0008,020,000,000
CFO
12.74b
+46.48%
14,733,000,00017,594,000,00013,353,000,00018,238,000,00016,587,000,00011,454,000,00020,240,000,00017,054,000,00017,765,000,00016,883,000,00014,512,000,00015,901,000,00016,470,000,00015,827,000,00012,588,000,00014,403,000,00032,580,000,00029,267,000,0008,700,000,00012,744,000,000
Dividend
Jul 25, 20240.42 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
IPO date
Jan 17, 1944
Employees
83,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT